Related Articles Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center. Inflamm Bowel Dis. 2019 Aug 10;: Authors: Bronswijk...
[ad_1] CT-P13 biosimilar is non-inferior to infliximab Source link [ad_1]
[ad_1] (MedPage Today) -- Analysis of real-world data show that CT-P13 is equivalent to infliximab in infliximab-naive patients with CD Source link [ad_1]
[ad_1] A large equivalence study shows similarity in efficacy and safety with the original formulation. Source link [ad_1]
[ad_1] (MedPage Today) -- With comparable safety and efficacy, drug choice may come down to cost Source link [ad_1]
© 2017 Worldnews Media LLC. All Rights Reserved.